PD23-04 THE IMPACT OF PROSTATIC URETHRAL LIFT ON ALPHA-BLOCKER DISCONTINUATION

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Surgical Therapy & New Technology IV (PD23)1 Sep 2021PD23-04 THE IMPACT OF PROSTATIC URETHRAL LIFT ON ALPHA-BLOCKER DISCONTINUATION Ankur Shah, Andrea Yeguez, Robert Zhang, and Robert Kovell Ankur ShahAnkur Shah More articles by this author , Andrea YeguezAndrea Yeguez More articles by this author , Robert ZhangRobert Zhang More articles by this author , and Robert KovellRobert Kovell More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002016.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Prostatic urethral lift (PUL) is a widely utilized minimally invasive treatment for benign prostatic hypertrophy (BPH) indicated in men with prostates less than 80 grams who desire preservation of erectile and ejaculatory function. Like many chronic conditions, men with symptomatic BPH tend to have poor medication adherence rates, estimated around 30%. While the majority of evidence demonstrates that PUL is safe and durable at 5 years, these studies primarily evaluate postoperative changes in patients’ urinary and erectile symptom scores and maximum urinary flow rates. There is sparse evidence on the impact of PUL on AB therapy. We therefore sought to evaluate whether PUL reduced the need for AB use postoperatively. We hypothesized PUL would decrease AB utilization. METHODS: We performed a retrospective analysis of 88 patients on AB therapy who underwent PUL from 2018 to 2020 at a single institution. We collected patients’ baseline demographic data and preoperative American Urological Association Symptom Score (AUASS). We also recorded the presence of diabetes mellitus, degree of bladder trabeculation, presence of urethral stricture, prior benign prostatic intervention and history of urinary retention. We then determined whether patients were on AB before and after their surgery using electronic records. Logistic regression was used to examine predictors of post-procedural discontinuation of AB. Paired student’s t-test and chi square test were utilized to compare continuous and categorical variables, respectively. RESULTS: No patients had prior prostatic surgical intervention or urethral strictures. Fifty-three percent of patients were able to discontinue AB therapy postoperatively. Patients with diabetes mellitus were more likely to require AB postoperatively (p<0.01). Age, race, AUASS, degree of bladder trabeculation, and a history of urinary retention requiring catheterization were not predictors of postoperative discontinuation of AB (Figure 1). CONCLUSIONS: PUL allowed more than half of patients undergoing surgery to discontinue use of their AB treatment. While further investigation is necessary, the findings of this study suggest PUL may be an effective alternative for men who have difficulty with or seek to avoid long-term medication use. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e421-e421 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ankur Shah More articles by this author Andrea Yeguez More articles by this author Robert Zhang More articles by this author Robert Kovell More articles by this author Expand All Advertisement Loading ...